Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises CELLINK in connection with listing on Nasdaq First North
Mandate

Vinge advises CELLINK in connection with listing on Nasdaq First North

October 07, 2016

Vinge has advised CELLINK AB (publ) in connection with its listing on Nasdaq First North.

The information memorandum was published on 7 October 2016 and the estimated first day of trading is 3 November 2016. The subscription price in the offer is SEK 26 per share, which corresponds to a pre-money value for CELLINK of approximately MSEK 156. No shares or other securities are being sold by existing shareholders in connection with the offer.

CELLINK develops and sells bioink and bioprinters. Bioink can be combined with conductive cells in order to print functional living tissue and, if future research is successful, complete human organs. CELLINK was founded in 2016 and has won several awards, both scientific and business related, for successful entrepreneurship.

 Vinge’s team consisted of responsible partner Anders Strid together with Frida Bäckegren (capital markets), Jonas Lindblad (employment), Joel Zetterström and Natalie Bäck (IT), Karin Wisenius (competition), Victor Ericsson (tax) and corporate assistant Camilla Andersson.    

Related

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024

Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest

Vinge advises Triton Smaller Mid-Cap Fund I (“Triton”) in connection with the divestment of Norstat, a leading data collector for market research, to Nalka Invest.
April 12, 2024